Recurrence analysis has emerged as a pivotal framework for understanding the intricate behaviour of complex dynamical systems. By constructing visual representations known as recurrence plots, ...

An open-label non–HLA-A*02 cohort showed a 0.7% annualized recurrence rate after primary immunization with GLSI-100, measured over an average 1.2 patient-years of exposure. Historical comparison to ...

Recent advances in healthcare research have increasingly leveraged routinely collected administrative data to monitor cancer recurrence. This approach circumvents the delays and resource-intensive ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an ...

Do patients with breast cancer with a low 21-gene recurrence score need regional node irradiation to reduce their risk of locoregional recurrence? Analysis of RxPONDER data suggests only a randomized ...

The long-term risk of distant recurrence for women with early breast cancer has declined significantly, a decades-long analysis of clinical trial data showed, largely a result of patients enrolling ...

The gut microbiome at time of surgery may significantly impact recurrence of colorectal cancer.An analysis of nearly 300 ...

Cancer patients are 40% less likely to experience recurrent acute venous thromboembolism (VTE) when treated with direct oral anticoagulants (DOACs) rather than low-molecular-weight heparin (LMWH), ...

The MarketWatch News Department was not involved in the creation of this content. STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a ...

Combining anthracycline and taxane for early-stage operable breast cancer was more effective than either anthracycline or taxane chemotherapy alone in reducing breast cancer recurrence and death, ...

Self-examination behavior varied markedly: roughly 20% reported none in the prior year, while about one-third examined weekly ...

OSLO, Norway, Dec. 8, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of a health economics abstract from the BRAVO study at the Society of ...